Yahoo
    NasdaqCM - Nasdaq Real Time Price USD

    RedHill Biopharma Ltd. (RDHL)

    0.4600 +0.0722 (+19.11%)
    As of 10:11:12 AM EST. Market Open.
    Loading Chart for RDHL
    Chart Range Bar
    Interval:
    In partnership with ChartIQ

    Recent News

    View More
    Two Leading Labs Confirm RHB-204 MAP-Killing Effect for RedHill's Crohn's Disease Candidate

    Two Leading Labs Confirm RHB-204 MAP-Killing Effect for RedHill's Crohn's Disease Candidate
    PR Newswire 3h ago
    $2.9 Million NCI Grant Awarded for Clinical Development of RedHill's Opaganib and CAR T-Cell Combination in Ultra-High-Risk Multiple Myeloma

    $2.9 Million NCI Grant Awarded for Clinical Development of RedHill's Opaganib and CAR T-Cell Combination in Ultra-High-Risk Multiple Myeloma
    PR Newswire 14d ago
    RedHill (RDHL) Acquires Rebyota and Clenpiq Commercialization Rights for $12M Upfront. Can Sales Outpace Royalties?

    RedHill (RDHL) Acquires Rebyota and Clenpiq Commercialization Rights for $12M Upfront. Can Sales Outpace Royalties?
    Insider Monkey 1mo ago
    RedHill Divests Talicia® to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities

    RedHill Divests Talicia® to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities
    CNW Group 2mo ago
    RedHill Biopharma Announces Up To $19.4 Million Private Placement

    RedHill Biopharma Announces Up To $19.4 Million Private Placement
    PR Newswire 4mo ago
    RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo

    RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo
    PR Newswire 4mo ago
    RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms

    RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms
    PR Newswire 4mo ago
    Inflammatory Bowel Disease Market to Experience Strong Uptake During the Forecast Period (2026-2036), Driven by Development of Next-generation Therapies Targeting IL-23, TL1A, and S1P Pathways | DelveInsight

    Inflammatory Bowel Disease Market to Experience Strong Uptake During the Forecast Period (2026-2036), Driven by Development of Next-generation Therapies Targeting IL-23, TL1A, and S1P Pathways | DelveInsight
    PR Newswire 3mo ago
    RedHill Biopharma Announces Operational Highlights and First Half 2026 Financial Results

    RedHill Biopharma Announces Operational Highlights and First Half 2026 Financial Results
    PR Newswire 1mo ago
    RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring’s Rebyota® and Clenpiq®

    RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring’s Rebyota® and Clenpiq®
    GlobeNewswire 2mo ago
    RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring's Rebyota® and Clenpiq®

    RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring's Rebyota® and Clenpiq®
    PR Newswire 2mo ago
    View More

    Related Tickers

    Mobilize your Website
    View Site in Mobile | Classic
    Share by: